Ponomarenko et al., 2007 - Google Patents
Anti-idiotypic antibody mimics proteolytic function of parent antigenPonomarenko et al., 2007
View PDF- Document ID
- 3371800237178002530
- Author
- Ponomarenko N
- Pillet D
- Paon M
- Vorobiev I
- Smirnov I
- Adenier H
- Avalle B
- Kolesnikov A
- Kozyr A
- Thomas D
- Gabibov A
- Friboulet A
- Publication year
- Publication venue
- Biochemistry
External Links
Snippet
Functional imaging of subtilisin Carlsberg active center by the idiotypic network yielded a catalytic anti-idiotypic antibody with endopeptidase, amidase, and esterase activities. A monoclonal antibody inhibitory to subtilisin (Ab1 5-H4) was employed as the template for …
- 102000004965 antibodies 0 title abstract description 296
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thiagarajan et al. | Monoclonal antibody light chain with prothrombinase activity | |
| Teufl et al. | Engineering strategies to overcome the stability–function trade-off in proteins | |
| Ponomarenko et al. | Anti-idiotypic antibody mimics proteolytic function of parent antigen | |
| Wörn et al. | Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering | |
| Saerens et al. | Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen | |
| Vincents et al. | Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding | |
| Ostertag et al. | ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro | |
| US20100040611A1 (en) | Antagonists of pcsk9 | |
| EP2083860A2 (en) | Antagonists of pcsk9 | |
| WO2008133647A2 (en) | Antagonists of pcsk9 | |
| Paul et al. | Antibodies as defensive enzymes | |
| Gololobov et al. | Innate antibody catalysis | |
| Rangnoi et al. | Enhancement and analysis of human antiaflatoxin b1 (AFB1) scFv antibody–ligand interaction using chain shuffling | |
| US12551571B2 (en) | Protease-cleavable substrates and methods of use thereof | |
| WO2024030843A1 (en) | Protease-cleavable moieties and methods of use thereof | |
| Reshetnyak et al. | Routes to covalent catalysis by reactive selection for nascent protein nucleophiles | |
| Pérez de la Lastra et al. | Antibodies targeting enzyme inhibition as potential tools for research and drug development | |
| Planque et al. | Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity | |
| Liu et al. | Rational design of antibody protease inhibitors | |
| Pillet et al. | Idiotypic network mimicry and antibody catalysis: lessons for the elicitation of efficient anti-idiotypic protease antibodies | |
| Hifumi et al. | New technologies to introduce a catalytic function into antibodies: A unique human catalytic antibody light chain showing degradation of β‐amyloid molecule along with the peptidase activity | |
| Uda et al. | Super catalytic antibody and antigenase | |
| Daventure et al. | Half‐Life Extension of the IgG‐Degrading Enzyme (IdeS) Using Fc‐Fusion Technology | |
| Danilov et al. | Fine epitope mapping of monoclonal antibody 5F1 reveals anticatalytic activity toward the N domain of human angiotensin-converting enzyme | |
| Hifumi et al. | A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain |